Risankizumab (trade name Skyrizi) is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in Europe, USA, Canada and Japan for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Property Value
dbo:abstract
  • Risankizumab (trade name Skyrizi) is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in Europe, USA, Canada and Japan for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. (en)
dbo:alternativeName
  • Skyrizi (en)
dbo:casNumber
  • 1612838-76-2
dbo:drugbank
  • DB14762
dbo:fdaUniiCode
  • 90ZX3Q3FR7
dbo:kegg
  • D11052
dbo:wikiPageEditLink
dbo:wikiPageExternalLink
dbo:wikiPageExtracted
  • 2019-06-15 20:11:14Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 50661119 (xsd:integer)
dbo:wikiPageLength
  • 4286 (xsd:integer)
dbo:wikiPageModified
  • 2019-05-21 06:52:18Z (xsd:date)
dbo:wikiPageOutDegree
  • 13 (xsd:integer)
dbo:wikiPageRevisionID
  • 898075007 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • Risankizumab (trade name Skyrizi) is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in Europe, USA, Canada and Japan for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. (en)
rdfs:label
  • Risankizumab (en)
foaf:isPrimaryTopicOf
owl:sameAs
is foaf:primaryTopic of